Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.

Introduction: CeFCiD was a multicenter phase II study comparing the efficacy of cetuximab (C), 5-flourouracil, and cisplatin with the same regimen adding docetaxel (D) in recurrent/metastatic head and neck cancer. The primary analysis trial did not demonstrate survival benefit from therapy intensification in first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The current analysis of the trial assessed the impact of treatment on quality of life (QoL).

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).

Background: The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN.

Methods: A total of 180 patients with R/M SCCHN (1:1) were assigned to receive either cisplatin (40 mg/m), docetaxel (40 mg/m) and 5-FU (2000 mg/m) at days 1 and 8 and cetuximab (400/250 mg/m) at days 1, 8 and 15 (DPFC) or standard cisplatin (100 mg/m) at day 1, 5-FU (1000 mg/m) at days 1-4 and cetuximab (400/250 mg/m) at days 1, 8 and 15 (PFC).

Patient performance with two types of multiple electrode intracochlear implant.

The functional results of 9 persons implanted with the Symbion Ineraid and 8 persons implanted with the Nucleus cochlear implant with the F0, F1, F2 coding strategy are reported. All patients were postlingually totally deaf, the patients implanted with the Symbion Ineraid were all above 40 years of age, while the Nucleus patients were with one exception under 40 years of age. The CID Everyday Sentences Test, the Helen Test and the Speech Tracking Test showed that all patients improved their communication skills when sound through the implant was added to lip-reading.